Skip to main content

Table 2 Meana GET score at baseline and follow-up visits by gender for GH-treated patients and controls

From: Design of the Growth hormone deficiency and Efficacy of Treatment (GET) score and non-interventional proof of concept study

 

GET score

Visit

Female control group

Female treated group

Male control group

Male treated group

N

Mean ± SD

N

Mean ± SD

N

Mean ± SD

N

Mean ± SD

1 (baseline)

5

51.14 ± 21.62

22

47.02 ± 22.29

10

49.78 ± 19.01

38

54.92 ± 19.84

2

5

48.84 ± 13.26

19

51.45 ± 13.07

10

47.02 ± 13.76

33

57.68 ± 16.47

3

4

53.49 ± 10.96

19

52.48 ± 16.09

9

43.22 ± 18.31

32

60.97 ± 14.92

4

3

43.65 ± 24.66

12

47.60 ± 14.70

9

40.58 ± 11.79

24

58.57 ± 13.91

5

3

49.84 ± 23.29

11

47.59 ± 14.11

6

49.19 ± 17.32

29

56.03 ± 14.67

  1. aNote the data presented are crude mean values and based on a variable number of patients
  2. GH growth hormone,GET Growth hormone deficiency and Efficacy of Treatment, N number of participants in whom GET score was calculated, SD standard deviation